Pharming Group N.V (PHGUF PINK) stock market data APIs
$1.7483
0(0%)
as of May 1, 2026
Try our APIs with
free plan!
Pharming Group N.V Financial Data Overview
Price chart is built with
Anychart
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Prev. Close
1.7483
Open
1.7483
High
1.7483
Low
1.7483
52 wk Range
0.913-2.17
Market Cap
1 363 M
P/E Ratio
0
Shares Outstanding
706 M
Revenue
376 M
EPS
0.007
Beta
0.12
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharming Group N.V data using free add-ons & libraries
Get Pharming Group N.V Fundamental Data
Pharming Group N.V Fundamental data includes:
- Net Revenue: 376 M
- EBITDA: 39 615 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharming Group N.V News
New
Pharming beats top-line estimates; introduces FY26 outlook
* Pharming press release [https://seekingalpha.com/pr/20434204-pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong] (PHAR [https://seekingalpha.com/symbol/PH...
Pharming Group Investor Day: 2026 revenue outlook tops Street as Joenja growth, readouts loom
Pharming Group logo Key Points 2026 guidance above Street: Pharming forecasted revenue of $405–$425 million for 2026 (8–13% growth vs. 2025), beating an analyst consensus of about $398 million, ...
European Penny Stocks To Watch In January 2026
The European markets have recently faced a downturn, with the pan-European STOXX Europe 600 Index and major national indices like France’s CAC 40 and Germany’s DAX experiencing declines amid renew...
3 European Penny Stocks With Market Caps Up To €1B
As the pan-European STOXX Europe 600 Index edges closer to record highs, optimism about future earnings and economic prospects is creating a favorable backdrop for investors. Penny stocks, although an...
Get Pharming Group N.V fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
